Dutasteride dosage for hair loss is an increasingly common topic among men seeking effective treatment for androgenetic alopecia. Although dutasteride is not licensed by the MHRA for hair loss in the UK, it is widely used off-label due to its potent dual inhibition of 5-alpha reductase — reducing DHT levels more substantially than finasteride. This article explains how dutasteride works, the standard dose used in clinical practice, how to take it safely, potential side effects to be aware of, and how to access it through private prescribers in the UK.

How Dutasteride Works for Hair Loss

Dutasteride reduces DHT by approximately 90–95% by inhibiting both type I and type II 5-alpha reductase isoforms, slowing follicle miniaturisation in androgenetic alopecia. It is used off-label for hair loss as it holds no MHRA licence for this indication.

Not sure if this is normal? Chat with one of our pharmacists →

Dutasteride belongs to a class of medicines known as 5-alpha reductase inhibitors (5-ARIs). It works by blocking the enzyme 5-alpha reductase, which converts testosterone into dihydrotestosterone (DHT) — the androgen most closely associated with androgenetic alopecia (male pattern hair loss). By reducing DHT levels in the scalp and bloodstream, dutasteride helps slow the miniaturisation of hair follicles and may promote measurable hair regrowth in some individuals.

Unlike finasteride, which selectively inhibits only the type II isoform of 5-alpha reductase, dutasteride inhibits both type I and type II isoforms. This dual inhibition results in a more pronounced reduction in serum DHT — the Avodart Summary of Product Characteristics (SmPC) and EMA EPAR report reductions of approximately 90–95% with dutasteride 0.5 mg daily, compared with approximately 70% for finasteride 1 mg daily in published studies. Some clinical trials and network meta-analyses (including those published in JAMA Dermatology) suggest dutasteride may be more effective than finasteride for androgenetic alopecia in some men, though direct head-to-head evidence remains limited and individual responses vary.

It is important to note that dutasteride is not currently licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of hair loss in the UK. Its licensed indication is benign prostatic hyperplasia (BPH) in adult men. The European Medicines Agency (EMA) has similarly not granted a hair loss indication. When prescribed for androgenetic alopecia, it is therefore used off-label.

Dutasteride is contraindicated in women, children, and adolescents. It is licensed only for use in adult men. Patients should have a thorough shared decision-making discussion with their prescriber — covering the off-label status, available evidence, risks, and alternatives — before commencing treatment.

How to Take Dutasteride Safely

The standard off-label dose is 0.5 mg orally once daily; capsules must be swallowed whole and never crushed or opened. Clinical effects on hair density typically take three to six months to appear, with optimal results at up to twelve months.

When used off-label for androgenetic alopecia in adult men, the most commonly studied dutasteride dosage for hair loss is 0.5 mg taken orally once daily. This is the only strength of dutasteride capsule available in the UK and mirrors the licensed dose used for BPH. Non-standard doses (such as 0.1 mg) are not available as a manufactured product in the UK and should not be attempted by opening or dividing capsules (see handling advice below).

Dutasteride capsules should be swallowed whole and must not be chewed, crushed, or opened, as the active ingredient can be absorbed through the oral mucosa and skin. If a capsule leaks or breaks, the affected area of skin should be washed immediately with soap and water. The capsules may be taken with or without food. Taking the medication at the same time each day helps maintain stable plasma concentrations.

Due to dutasteride's exceptionally long elimination half-life of approximately five weeks, it accumulates in the body over time. Meaningful clinical effects on hair density are typically not observed until three to six months of continuous use, with optimal results often taking up to twelve months. Importantly, the benefits of treatment are maintained only while continuing therapy — hair loss is likely to resume within months of stopping dutasteride.

Contraindications and key cautions include:

• Dutasteride is contraindicated in women, children, and adolescents.

• It is contraindicated in individuals with known hypersensitivity to dutasteride, other 5-ARIs, or any excipient. The capsules contain a soya derivative; patients with a soya or peanut allergy should not take dutasteride and must inform their prescriber.

• Hepatic impairment: Dutasteride should be used with caution in patients with mild to moderate hepatic impairment and is not recommended in those with severe hepatic impairment, as it has not been studied in this group.

• Women of childbearing potential must not handle broken or leaking capsules, as dutasteride is teratogenic and may cause abnormalities of the external genitalia in a male foetus.

• Men taking dutasteride should not donate blood during treatment and for at least six months after stopping, to prevent inadvertent exposure to a pregnant recipient.

Drug interactions: Dutasteride is metabolised primarily by CYP3A4 and CYP3A5. Potent inhibitors of these enzymes — including ketoconazole, itraconazole, ritonavir, verapamil, and diltiazem — may increase dutasteride plasma concentrations. Inform your prescriber of all medicines, including over-the-counter products and supplements, before starting treatment.

Worried about interactions with other medications? Speak to one of our pharmacists →

Monitoring: Prescribers should record a baseline prostate-specific antigen (PSA) measurement before starting treatment (and consider a digital rectal examination where clinically appropriate). Dutasteride reduces PSA levels by approximately 40–50% after six months of use; a new baseline should be established at around six months to allow meaningful interpretation of subsequent results. Any confirmed rise in PSA from the on-treatment nadir warrants further evaluation regardless of whether values remain within the normal range. Patients planning to father children should be aware that changes in semen parameters (including reduced sperm count, volume, and motility) have been reported with dutasteride; these effects are generally considered reversible after stopping treatment, but men with fertility concerns should discuss this with their prescriber before starting.

Possible Side Effects and Risks to Be Aware Of

The most common side effects are sexual in nature, including reduced libido, erectile dysfunction, and ejaculatory disorders, affecting a minority of users. Mood changes, PSA reduction, altered semen parameters, and rare hypersensitivity reactions also require monitoring.

As with all medicines, dutasteride carries a risk of side effects, and patients should be counselled thoroughly before starting treatment. The most commonly reported adverse effects relate to its hormonal mechanism of action — specifically, the significant reduction in circulating DHT levels.

Sexual side effects are among the most frequently discussed and include:

• Reduced libido (decreased sex drive)

• Erectile dysfunction

• Ejaculatory disorders, including reduced ejaculate volume

• Gynaecomastia (breast tissue enlargement or tenderness in men)

These effects are reported in a minority of users and may resolve upon discontinuation. However, as with other 5-ARIs, there have been reports of sexual dysfunction persisting after stopping treatment. The evidence for a dutasteride-specific persistent syndrome is limited, and there is no official regulatory classification of such a syndrome specifically for dutasteride; however, patients should be made aware of this possibility and encouraged to report any ongoing symptoms to their prescriber promptly.

Mood and psychological effects: Depression, low mood, and — in rare cases — suicidal ideation have been reported in association with 5-ARIs, including finasteride (as noted in MHRA Drug Safety Updates). Similar reports exist for dutasteride. Patients experiencing any mood changes, depressive symptoms, or thoughts of self-harm should seek immediate medical advice.

PSA and prostate monitoring: Dutasteride reduces PSA levels by approximately 40–50% after six months of use. Prescribers should document a baseline PSA value, establish a new on-treatment baseline at approximately six months, and investigate any confirmed rise from that nadir, as this may indicate prostate pathology irrespective of the absolute value.

Fertility and semen: Changes in semen parameters (reduced sperm count, volume, and motility) have been reported in some men taking dutasteride. These effects are generally considered reversible after stopping treatment. Men who are planning to father children should discuss this with their prescriber before starting.

Breast changes: Patients should be vigilant for breast lumps, persistent pain, or nipple discharge and seek prompt medical assessment if these occur, to exclude the rare possibility of male breast cancer.

Other side effects may include dizziness, rash, or hypersensitivity reactions. Patients should seek urgent medical advice if they experience symptoms of a severe allergic reaction, such as facial swelling, difficulty breathing, or widespread rash.

Reporting side effects: Patients and healthcare professionals are encouraged to report suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. Regular follow-up with the prescribing clinician is advisable to monitor tolerability and treatment response.

Accessing Dutasteride Through the NHS or Private Prescribers

Dutasteride for hair loss is not routinely available on the NHS and is most commonly accessed through private dermatology clinics or regulated online prescribing services. Patients should verify their prescriber is GMC-registered and the dispensing pharmacy holds GPhC registration.

Because dutasteride is not licensed in the UK for the treatment of hair loss, it is not routinely available on the NHS for this indication. NHS prescribing is guided by NICE recommendations and licensed indications; androgenetic alopecia is not currently a condition for which dutasteride would be prescribed within standard NHS pathways. Patients seeking treatment for hair loss through their GP are more likely to be directed towards licensed options such as topical minoxidil (available over the counter) or referred to a dermatologist for further assessment.

For those wishing to access dutasteride specifically for hair loss, the most common route in the UK is through private dermatology clinics or specialist hair loss services. A qualified prescriber — such as a consultant dermatologist or a registered independent prescriber working within a regulated clinic — can legally prescribe dutasteride off-label following a thorough clinical assessment, a documented informed consent discussion, and clear recording of the rationale for off-label use. This aligns with guidance from the General Medical Council (GMC) on prescribing unlicensed or off-label medicines (Good practice in prescribing and managing medicines and devices).

Some regulated online prescribing services also offer dutasteride for hair loss in the UK. Patients using online services should verify that:

• The prescriber is registered with the GMC (check via the GMC online register).

• The pharmacy dispensing the medicine is registered with the General Pharmaceutical Council (GPhC).

• The provider is registered with the Care Quality Commission (CQC) if operating as a regulated healthcare provider in England (equivalent bodies apply in Scotland, Wales, and Northern Ireland).

• Avoid purchasing dutasteride from unregulated online sources, as product quality, authenticity, and safety cannot be guaranteed.

Consultation and dispensing fees for private prescriptions vary; patients should discuss costs with their chosen provider. Patients should also discuss realistic expectations regarding treatment outcomes, the off-label nature of the medicine, the need for long-term commitment, and the likelihood that hair loss will resume if treatment is stopped, before commencing dutasteride.

Frequently Asked Questions